Norfenfluramine
From Wikipedia, the free encyclopedia
| Norfenfluramine | |
|---|---|
 |
|
|
1-[3-(Trifluoromethyl)phenyl]propan-2-amine |
|
|
Other names
3-Trifluoromethylamphetamine |
|
| Identifiers | |
| CAS number | 19036-73-8  |
| PubChem | 15897 |
| ChemSpider | 15108 |
| IUPHAR ligand | 215 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C10H12F3N |
| Molar mass | 203.2 g mol−1 |
 (verify) (what is:  / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references |
Norfenfluramine, or 3-trifluoromethylamphetamine, is a drug of the amphetamine family which behaves as a serotonin and norepinephrine releasing agent and potent 5-HT2A, 5-HT2B, and 5-HT2C agonist. The action of norfenfluramine on 5-HT2B receptors on heart valves leads to a characteristic pattern of heart failure following proliferation of cardiac fibroblasts on the tricuspid valve, known as cardiac fibrosis.[1] This side effect led to the withdrawal of fenfluramine as an anorectic agent worldwide, and to the withdrawal of benfluorex in Europe,[2] as both fenfluramine and benfluorex form norfenfluramine as an active metabolite.
[edit] See also
[edit] References
- ^ Setola, V.; Dukat, M.; Glennon, R. A.; Roth, B. L. (2005). "Molecular Determinants for the Interaction of the Valvulopathic Anorexigen Norfenfluramine with the 5-HT2B Receptor" (pdf). Molecular Pharmacology 68 (1): 20–33. doi:10.1124/mol.104.009266. PMID 15831837. http://molpharm.aspetjournals.org/content/68/1/20.full.pdf.
- ^ "European Medicines Agency recommends withdrawal of benfluorex from the market in European Union" (pdf). European Medicines Agency. 2009-12-18. http://www.emea.europa.eu/pdfs/human/referral/benfluorex/Benfluorex_81503309en.pdf.
|
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
